CA
BPMC

Continuum Advisory’s Blueprint Medicines BPMC Stock Holding History

Continuum Advisory’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21
Closed -$2.01K – 1870
2024
Q3 		$2.01K Sell
21
-15
-42% -$1.49K ﹤0.01% 1426
2024
Q2 		$3.88K Sell
36
-1
-3% -$100 ﹤0.01% 1137
2024
Q1 		$4.01K Buy
+37
New +$3.17K ﹤0.01% 1111

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Continuum Advisory's BPMC Position: Q4 2024 in Review

Continuum Advisory sold out of Blueprint Medicines (BPMC) in Q4 2024, closing a stake of 21 shares — an estimated $2.01K sold.

Continuum Advisory first reported a position in BPMC in Q1 2024 and held it in 3 quarters. The position peaked at $4.01K in Q1 2024. 345 funds tracked by Wall St. Rank hold BPMC as of Q4 2024.

  • Continuum Advisory reported no remaining Blueprint Medicines position as of Q4 2024 after selling out during the quarter.
  • Continuum Advisory sold 21 Blueprint Medicines shares in Q4 2024, an estimated $2.01K.
  • Continuum Advisory first reported a position in Blueprint Medicines in Q1 2024 and held it in 3 quarters.
  • Continuum Advisory's Blueprint Medicines position peaked at $4.01K in Q1 2024.
  • 345 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2024.

Based on Continuum Advisory's 13F filing for Q4 2024, filed 18 Feb 2025.